Exact Sciences Corporation (EXAS) DCF Valuation
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Exact Sciences Corporation (EXAS) Bundle
Designed for accuracy, our Exact Sciences (EXAS) DCF Calculator enables you to evaluate Exact Sciences Corporation's valuation with real-time financial data and complete flexibility to modify all key parameters for improved projections.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 876.3 | 1,491.4 | 1,767.1 | 2,084.3 | 2,499.8 | 3,290.7 | 4,331.9 | 5,702.6 | 7,506.9 | 9,882.2 |
| Revenue Growth, % | 0 | 70.19 | 18.49 | 17.95 | 19.93 | 31.64 | 31.64 | 31.64 | 31.64 | 31.64 |
| EBITDA | -217.7 | -632.9 | -617.7 | -386.7 | 41.9 | -784.0 | -1,032.0 | -1,358.6 | -1,788.5 | -2,354.3 |
| EBITDA, % | -24.85 | -42.43 | -34.96 | -18.56 | 1.68 | -23.82 | -23.82 | -23.82 | -23.82 | -23.82 |
| Depreciation | 55.7 | 179.1 | 206.2 | 226.2 | 206.6 | 323.5 | 425.8 | 560.5 | 737.9 | 971.3 |
| Depreciation, % | 6.35 | 12.01 | 11.67 | 10.85 | 8.27 | 9.83 | 9.83 | 9.83 | 9.83 | 9.83 |
| EBIT | -273.4 | -811.9 | -823.9 | -612.9 | -164.7 | -1,107.4 | -1,457.8 | -1,919.1 | -2,526.3 | -3,325.7 |
| EBIT, % | -31.2 | -54.44 | -46.62 | -29.41 | -6.59 | -33.65 | -33.65 | -33.65 | -33.65 | -33.65 |
| Total Cash | 323.7 | 1,840.0 | 1,030.5 | 632.1 | 777.6 | 1,689.3 | 2,223.9 | 2,927.5 | 3,853.8 | 5,073.2 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 130.4 | 233.2 | 216.6 | 158.0 | 203.6 | 385.0 | 506.8 | 667.2 | 878.3 | 1,156.2 |
| Account Receivables, % | 14.88 | 15.64 | 12.26 | 7.58 | 8.15 | 11.7 | 11.7 | 11.7 | 11.7 | 11.7 |
| Inventories | 61.7 | 92.3 | 105.0 | 118.3 | 127.5 | 197.1 | 259.4 | 341.5 | 449.6 | 591.8 |
| Inventories, % | 7.04 | 6.19 | 5.94 | 5.67 | 5.1 | 5.99 | 5.99 | 5.99 | 5.99 | 5.99 |
| Accounts Payable | 26.0 | 35.7 | 67.8 | 74.9 | 78.8 | 104.9 | 138.1 | 181.8 | 239.4 | 315.1 |
| Accounts Payable, % | 2.96 | 2.39 | 3.84 | 3.59 | 3.15 | 3.19 | 3.19 | 3.19 | 3.19 | 3.19 |
| Capital Expenditure | -171.8 | -64.4 | -135.8 | -214.5 | -124.2 | -308.4 | -406.0 | -534.5 | -703.6 | -926.2 |
| Capital Expenditure, % | -19.61 | -4.31 | -7.68 | -10.29 | -4.97 | -9.37 | -9.37 | -9.37 | -9.37 | -9.37 |
| Tax Rate, % | -1.19 | -1.19 | -1.19 | -1.19 | -1.19 | -1.19 | -1.19 | -1.19 | -1.19 | -1.19 |
| EBITAT | -85.4 | -803.8 | -582.5 | -604.2 | -166.7 | -884.8 | -1,164.8 | -1,533.4 | -2,018.6 | -2,657.2 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -367.7 | -812.7 | -476.1 | -540.0 | -135.2 | -1,094.7 | -1,296.0 | -1,706.1 | -2,245.9 | -2,956.5 |
| WACC, % | 8.66 | 9.26 | 9.01 | 9.25 | 9.27 | 9.09 | 9.09 | 9.09 | 9.09 | 9.09 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -6,906.0 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -3,016 | |||||||||
| Terminal Value | -42,533 | |||||||||
| Present Terminal Value | -27,530 | |||||||||
| Enterprise Value | -34,436 | |||||||||
| Net Debt | 1,949 | |||||||||
| Equity Value | -36,385 | |||||||||
| Diluted Shares Outstanding, MM | 180 | |||||||||
| Equity Value Per Share | -201.98 |
What You Will Receive
- Genuine EXAS Data: Preloaded financial metrics – including revenue and EBIT – based on actual and forecasted figures.
- Comprehensive Customization: Modify all essential parameters (yellow cells) such as WACC, growth %, and tax rates.
- Immediate Valuation Adjustments: Automatic recalculations to evaluate the effects of changes on Exact Sciences Corporation’s fair value.
- Flexible Excel Template: Designed for quick modifications, scenario analysis, and in-depth projections.
- Efficient and Precise: Avoid constructing models from the ground up while ensuring accuracy and adaptability.
Key Features
- 🔍 Real-Life EXAS Financials: Pre-filled historical and projected data for Exact Sciences Corporation (EXAS).
- ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Built-in formulas calculate Exact Sciences’ intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize Exact Sciences’ valuation instantly after making changes.
- Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.
How It Works
- 1. Download the Template: Acquire and open the Excel file featuring Exact Sciences Corporation’s (EXAS) preloaded data.
- 2. Adjust Key Inputs: Modify essential parameters such as growth rates, WACC, and capital expenditures.
- 3. Instant Results: The DCF model automatically computes intrinsic value and NPV in real-time.
- 4. Explore Scenarios: Analyze various forecasts to evaluate different valuation possibilities.
- 5. Present with Assurance: Share professional valuation findings to bolster your strategic decisions.
Why Choose Exact Sciences Corporation (EXAS)?
- Innovative Solutions: Cutting-edge technologies for accurate cancer detection and diagnostics.
- Proven Results: Backed by extensive clinical research and data demonstrating effectiveness.
- Patient-Centric Approach: Focused on improving patient outcomes and enhancing the healthcare experience.
- Comprehensive Support: Dedicated resources and support for healthcare providers and patients alike.
- Industry Recognition: A trusted leader in the field of molecular diagnostics and precision medicine.
Who Should Use Exact Sciences Corporation (EXAS) Products?
- Healthcare Investors: Make informed decisions with advanced diagnostic tools and technologies.
- Medical Researchers: Streamline data analysis with comprehensive research solutions tailored for innovation.
- Clinicians: Enhance patient care by utilizing precise and reliable testing methodologies.
- Health Policy Makers: Gain insights into the impact of diagnostics on public health initiatives.
- Students and Educators: Explore real-world applications of molecular diagnostics in academic settings.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Exact Sciences Corporation (EXAS) historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Exact Sciences Corporation (EXAS).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.